Jurnista 16 mg tablets Canada

Description

### JURNISTA 16 MG TABLETS CANADA

### UNDERSTANDING THE OROS® DELIVERY SYSTEM IN JURNISTA

Hydromorphone hydrochloride is a potent semi-synthetic opioid agonist derived from morphine. It primarily binds to mu-opioid receptors in the central nervous system, altering the perception of and emotional response to pain. Jurnista was designed as a **prolonged-release tablet** using OROS® technology to provide around-the-clock pain management for patients requiring continuous, long-term opioid therapy. The OROS® system allowed for a controlled, consistent release of hydromorphone over a 24-hour period .

### INDICATIONS FOR USE OF JURNISTA 16 MG

Jurnista was indicated for the management of moderate to severe chronic pain in patients who required continuous, around-the-clock opioid analgesia . It was intended for patients who required daily, continuous, long-term treatment of opioid-responsive pain where other treatment options had failed, were contraindicated, not tolerated, or were otherwise inappropriate.

**Important Limitations of Use:**
– **Not for Acute Pain:** Jurnista was not indicated as an as-needed (PRN) analgesic or for acute pain management.
– **Not for Opioid-Naïve Patients:** The recommended starting dose for patients not on routine opioid therapy was generally 8 mg once daily, with the 16 mg strength being more appropriate for patients who had already been receiving opioids .
– **Not for Mild Pain:** It was not indicated for pain that was mild or would resolve in a few days.
– **Pediatric Use:** Jurnista was not recommended for use in children and adolescents below age 18 years due to insufficient data on safety and efficacy.

### CONTRAINDICATIONS, WARNINGS, AND PRECAUTIONS

As a potent opioid, Jurnista carried serious warnings, including risks of addiction, abuse, misuse, life-threatening respiratory depression, accidental exposure, and neonatal opioid withdrawal syndrome. The extended-release formulation was designed to release medication slowly; breaking, crushing, chewing, or dissolving the tablet could cause a potentially fatal overdose .

Patients were advised not to drink alcohol while taking this medication, as it could intensify its effects and increase the risk of respiratory depression . Because the product has been discontinued, patients should **not** seek this specific formulation.

### DOSAGE AND ADMINISTRATION OF JURNISTA 16 MG

The 16 mg strength was intended for patients already on stable, around-the-clock opioid therapy. The medication was taken once daily, typically at the same time each day . Patients were instructed to swallow tablets whole and not to split, crush, or chew them . It could be taken with or without food.

Conversion from other opioids required careful calculation . No fixed conversion ratio was considered satisfactory for all patients; therefore, conversion to Jurnista was followed by close patient monitoring and titration .

### DISCONTINUATION IN CANADA AND CURRENT AVAILABILITY

**Critical Update:** Jurnista 16 mg tablets were **discontinued in Canada effective November 1, 2018** by the manufacturer, Janssen Inc. . The product was cancelled post-market for business reasons . As of August 2026, this product is no longer available in Canada. The 16 mg strength tablet (DIN: 02337282) is no longer marketed .

Patients who were previously prescribed Jurnista 16 mg should consult their healthcare provider immediately for an appropriate alternative medication. Options may include other extended-release hydromorphone products (such as Hydromorph Contin) or different opioid formulations, with careful conversion and titration under medical supervision.

### PATIENT INFORMATION FOR FORMER JURNISTA USERS

If you were previously taking Jurnista, key instructions that applied to this medication included:
– Take exactly as directed by your healthcare professional.
– Swallow tablets whole; do not crush, chew, or dissolve.
– Do not share or sell the medication.
– Avoid driving or operating machinery until you understand how the medication affects you.
– Report any side effects promptly.

**Current Transition:** You should not attempt to obtain Jurnista 16 mg as it is discontinued. Your healthcare provider can help you transition to an alternative opioid analgesic.

### STORAGE, HANDLING, AND DISPOSAL

Former Jurnista tablets should have been stored at room temperature, protected from light, in the original child-resistant packaging. Unused or expired tablets should be disposed of through pharmacy take-back programs or authorized collection sites.

### FREQUENTLY ASKED QUESTIONS ABOUT JURNISTA 16 MG

**Is Jurnista 16 mg still available in Canada?** No. Jurnista 16 mg tablets were discontinued in Canada effective November 1, 2018, and are no longer available .

**What should I do if I was taking Jurnista 16 mg?** You should consult your healthcare provider immediately to transition to an alternative pain management medication. Do not abruptly stop taking opioids, as withdrawal symptoms may occur. Your doctor can help you safely switch to another medication.

**Is there a substitute for Jurnista?** Yes. Alternative extended-release hydromorphone products (such as Hydromorph Contin) or other opioid formulations may be available. Your healthcare provider will determine the most appropriate alternative based on your individual needs.

### HISTORY AND MANUFACTURING OF JURNISTA BY JANSSEN IN CANADA

Janssen Inc. manufactured Jurnista as a once-daily hydromorphone product using OROS® technology. The product was marketed in Canada beginning April 13, 2010 . The 16 mg tablet was one of several strengths available, with the product line including 4 mg, 8 mg, 16 mg, 32 mg, and 64 mg strengths . The 16 mg tablet was described as a yellow, round, biconvex tablet, with ‘HM 16’ printed in black ink on one side . The product was discontinued by the manufacturer on November 1, 2018, for business reasons .

### THE CANADIAN REGULATORY FRAMEWORK FOR JURNISTA

Jurnista was regulated under the Controlled Drugs and Substances Act (CDSA) as a narcotic (CDSA I), the Narcotic Control Regulations, and the Food and Drugs Act . Prescribing, dispensing, record-keeping, and monitoring followed both federal and provincial requirements.

### SUPPORT RESOURCES FOR CANADIAN PATIENTS

– Provincial pain clinics and palliative care services.
– Addiction and mental health support programs.
– Public naloxone distribution initiatives.
– Health Canada and provincial ministry resources for safe medication use.

—

**DISCLAIMER:** This article is for informational and educational purposes only and is not medical advice. Hydromorphone is a potent Schedule I controlled narcotic available in Canada only by prescription. **Jurnista 16 mg is discontinued and no longer available in Canada.** Patients who were on this medication should consult their healthcare provider for a safe transition to an alternative therapy. In an emergency, call 911 or your provincial poison control centre immediately.

### CONCLUSION: STATUS OF JURNISTA 16 MG IN CANADA

Jurnista 16 mg tablets are no longer available in Canada as of November 1, 2018. Patients who were previously prescribed this medication should work with their healthcare provider to transition to an alternative pain management therapy. Do not attempt to seek this discontinued product, and do not abruptly stop opioid therapy without medical supervision.

**DISCLAIMER:** This article is for informational and educational purposes only and does not constitute medical advice. Jurnista 16 mg tablets are a prescription-only Schedule I controlled narcotic under the Controlled Drugs and Substances Act in Canada. It was authorized by Health Canada for the management of moderate to severe chronic pain in adults requiring continuous opioid analgesia. Always consult your licensed Canadian healthcare professional for personalized medical advice. Individual responses vary. Always verify the most current product information on the Health Canada Drug Product Database.

**CRITICAL PRODUCT STATUS UPDATE:** Jurnista 16 mg tablets have been **discontinued in Canada** and are no longer available. The product was cancelled post-market by the manufacturer, Janssen Inc., effective October 31, 2018, for business reasons .

—

**Jurnista 16 mg Tablets Canada** was a once-daily, extended-release opioid analgesic produced by Janssen Inc., based in Toronto, Ontario . The product received its Notice of Compliance from Health Canada on November 18, 2009, and was marketed in Canada beginning April 13, 2010 . The 16 mg strength tablet (DIN: 02337282) contained 16 mg of hydromorphone hydrochloride as the active ingredient . Unlike immediate-release hydromorphone formulations, Jurnista utilized the patented **OROS® (oral osmotic pump) technology** to deliver a membrane-controlled, activated process that released the medication at a constant rate over 24 hours .